A Phase 1 interventional study of [14C]X842 in Gastroesophageal Reflux Disease, sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-06.
Sponsored by Jiangsu Sinorda Biomedicine Co., Ltd · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Gastroesophageal Reflux with a site in China — 15 open to participants now, 16 under way, none of them phase 3. Gastroesophageal Reflux · China.
Among the 55 studies in Gastroesophageal Reflux with a site in China, this one is the 37th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2022, is one of 2 in phase 1, and was the 45th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →15 of the 55 studies in Gastroesophageal Reflux with a site in China are open now. Recruiting first, the newest first:
Xinghua Liu · Sites in China
Ages 18–65
Beijing Friendship Hospital · Sites in China
Ages 18–90
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Shanghai Hutchison Pharmaceuticals Limited · Sites in China
Ages 18–75
Beijing Friendship Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7 · Phase 4 2
First in 2003; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 89 across the 38 interventional studies, 1,625 across the 17 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 55 have an industry lead sponsor. The 10 most frequent:
Jiangsu Sinorda Biomedicine Co., Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Jiangsu Sinorda Biomedicine Co., Ltd has 3 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
4 of the studies in Gastroesophageal Reflux with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07749989Beijing Friendship HospitalA Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset | 2027-04 |
| NCT06755671Shanghai Hutchison Pharmaceuticals LimitedA Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms | 2027-06-30 |
| NCT07795645Beijing Friendship HospitalValidating a Medical AI Fine-Tuning Platform for Major Diseases | 2027-08-31 |
| NCT07854613China-Japan Friendship HospitalDe Novo Gastroesophageal Reflux Disease After Sleeve Gastrectomy With and Without Omentopexy | 2027-10-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Gastroesophageal Reflux with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C]X842 in healthy adult male subjects. The study plans to enroll 6 to 8 healthy male subjects in China to ensure at least 4 evaluable subjects.
The healthy male subjects will be screened no more than 14 days before the dose (D-14 through D-3) and admitted to the clinical research center 2 days before the dose (D-2). The subjects will receive a single oral administration of approximately 50 mg/100 µCi [14C]X842 suspension orally on an empty stomach on day 1.
Urine and feces samples will be all collected from the subjects before and at specified intervals between 0 and 312 hours after taking the drug and blood samples will be collected at specified time points between 0 and 216 hours before and after taking the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Auxiliary Examinations:
Subjects testing positive for: surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab),Treponema pallidum antibody (syphilis screening);
-Medication History:
Subjects with use of any prescription medications, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (e.g., vitamins, calcium) within 14 days prior to screening;
-Disease and Surgical History
Subjects with regular/ongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease;
-life style
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
a single oral administration of approximately 50 mg/ 100 µCi \[14C\]X842 suspension orally on an empty stomach on day 1
Drug: [14C]X842
50 mg/100 µCi \[14C\] X842 suspension
Also known as: [14C]X842 suspension
Mass balance: the cumulative excretion rate
To collect the total radioactive substances in excreta (urine and feces) and to calculate the cumulative excretion rate
Time frame: 22 days
Tmax (time to maximum observed concentration)
Tmax parameters of the total radioactivity in plasma
Time frame: 22 days
Cmax(maximum concentration)
Cmax parameters of the total radioactivity in plasma
Time frame: 22 days
AUC(area under curve)
AUC parameters of the total radioactivity in plasma
Time frame: 22 days
t1/2 (terminal elimination half-life)
t1/2 parameters of the total radioactivity in plasma
Time frame: 22 days
MRT (mean residence time)
MRT parameters of the total radioactivity in plasma
Time frame: 22 days
Vd/F(apparent volume of distribution)
Vd/F parameters of the total radioactivity in plasma
Time frame: 22 days
whole blood/plasma ratio for the total radioactivity concentration at different time points
whole blood/plasma ratio for the total radioactivity concentration at different time points
Time frame: 22 days
Percentage of the drug and its metabolites in plasma, urine and feces to the administered dose
Exposure in plasma; percentage of the drug and its metabolites in urine and feces to the administered dose; identification of major metabolites in plasma, urine and feces
Time frame: 22 days
The nature and severity of AEs based on NCI-CTC AE V5.0
The nature and severity of adverse events were adjudicated in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)
Time frame: 22 days
The nature and incidence and severity of SAEs based on NCI-CTC AE V5.0
The nature and severity of serious adverse events were adjudicated in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)
Time frame: 22 days
12-Electrocardiograms (ECG)
the data collection of heart rate, PR interval, QRS interval, QT, QTc, on D-1 and 2 hours (±30 min) after administration
Time frame: 22 days
vital signs of pulse
pulse (beats per minute)
Time frame: 22 days
vital signs of body temperature
body temperature (℃)
Time frame: 22 days
vital signs of blood pressure
measurements included systolic (mmHg) and diastolic (mmHg).
Time frame: 22 days
vital signs of respiratory rate
respiratory rate (breaths per minute).
Time frame: 22 days
Hematology - Number of participants with clinically significant abnormalities
including White blood cell count, lymphocyte count, neutrophil count, red blood cell count, hemoglobin, platelet count
Time frame: 22 days
Blood Chemistry - Number of participants with clinically significant abnormalities
Blood Biochemistry including: Total Bilirubin (TBIL), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-Glutamyl Transferase (GGT), Alkaline Phosphatase (ALP), Total Protein (TP), Albumin (ALB), Urea, Creatinine (Cr), Uric Acid (UA), Glucose (GLU), Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Low-Density Lipoprotein Cholesterol (LDL-C), Triglycerides (TG), Potassium (K+), Sodium (Na+), Chloride (Cl-), Lactate Dehydrogenase (LDH), Creatine Kinase (CK), Amylase (AMY).
Time frame: 22 days
Coagulation - Number of participants with clinically significant abnormalities
including Prothrombin Time (PT), Thrombin Time (TT), Activated Partial ,, hromboplastin Time (APTT/aPTT),Fibrinogen (FIB/Fg), International Normalized Ratio (INR)
Time frame: 22 days
Urinalysis - Number of participants with clinically significant abnormalities
Urinalysis including Urinary protein, urine sugar, urine ketone bodies, red blood cells, white blood cells, pH value
Time frame: 22 days
Fecal Occult Blood Test (FOBT) - Number of participants with positive result
Fecal Occult Blood Test (FOBT) result
Time frame: 22 days
Ran from Jun 2022 to primary completion in Jul 2022, 0 months.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 0 months is below that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linaprazan glurate
Jiangsu Sinorda Biomedicine Co., Ltd